Rx Fraud Cases: IG Integrity Agreements May Be As Costly As Settlements
Executive Summary
The pharmaceutical industry should pay greater attention to the costs associated with corporate integrity agreements included in False Claims Act liability settlements, attorney Lynn Snyder (Epstein Becker & Green) suggested.
You may also be interested in...
Compliance Officers Make Good “Whistleblowers” – U.S. Prosecutor Sheehan
Corporate compliance officers will make up the next wave of "whistleblowers" in health care fraud cases, Philadelphia Associate U.S. Attorney James Sheehan said at the Food & Drug Law Institute Enforcement & Litigation Conference in Washington, D.C. Sept. 22
Compliance Officers Make Good “Whistleblowers” – U.S. Prosecutor Sheehan
Corporate compliance officers will make up the next wave of "whistleblowers" in health care fraud cases, Philadelphia Associate U.S. Attorney James Sheehan said at the Food & Drug Law Institute Enforcement & Litigation Conference in Washington, D.C. Sept. 22
Lilly Takes Separate Track On IG; Compliance Guide Is Not A PhRMA Issue
Lilly plans to comment on the HHS Inspector General's pharmaceutical compliance guidance independent of an industry-wide compliance working group.